IX BIOPHARMA LTD.

(Company Registration Number 200405621W) (Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN \$\$5,000,000 - RECEIPT OF LISTING AND QUOTATION NOTICE

The Board of Directors of iX Biopharma Ltd. (the "**Company**") (the "**Board**" or the "**Directors**") refers to its announcements dated 28 October 2025 in relation to (a) the entry into a placement agreement with Oversea-Chinese Banking Corporation Limited and (b) the results of the Proposed Placement (collectively, the "**Announcements**").

Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Announcements.

Further to the Announcements, the Board is pleased to announce that the Company has on 30 October 2025, received the listing and quotation notice ("LQN") from the Singapore Exchange Securities Trading Limited ("SGX-ST") for the listing and quotation of up to 67,000,000 New Shares pursuant to the Proposed Placement, subject to compliance with the listing requirements of the SGX-ST. The LQN is not to be taken as an indication of the merits of the Proposed Placement, the New Shares, the Company and/or its subsidiaries.

The Company will continue to keep its shareholders updated and release announcements relating to the Proposed Placement (including any material developments and progress made) as may be appropriate from time to time.

Shareholders and potential investors should note that the Proposed Placement is subject to the fulfilment of, inter alia, the conditions set out under the Placement Agreement, and should exercise caution when trading in the Shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board IX BIOPHARMA LTD.

Eddy Lee Yip Hang Chairman & CEO

30 October 2025

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.